Optomed Plc         Stock Exchange Release    1 September 2020 at 10.30, Helsinki

Change in Optomed's holding of treasury shares

Optomed has conveyed 7,622 treasury shares to the members of the Board of Directors as a part of the Board members' annual remuneration in accordance with the decision of the Annual General Meeting 2020. The amount of shares is based on the monthly remuneration decided by the Annual General Meeting and Optomed's value weighted average share price on 27 August 2020. Furthermore, Mr Jun Wu has informed Optomed that he waives his board remuneration for the current board term.

Furthermore, a total of 27,500 of shares have been subscribed for under the Company's stock option plans 2009A and 2018C and Optomed has used treasury shares for the share subscriptions. The subscribed shares will be delivered to the subscribers on 3 September 3 2020.

The total amount of treasury shares is now 775,878.
 

Optomed Plc

Further enquiries

Sakari Knuutti, CLO, Optomed Plc, sakari.knuutti@optomed.com

Optomed in Brief 

Optomed is a Finnish medical technology company and one of the leading providers of handheld fundus cameras. Optomed combines handheld cameras with software and artificial intelligence with the aim to transform the diagnostic process of blinding eye-diseases such as rapidly increasing diabetic retinopathy. In its business Optomed focuses on eye-screening devices and software solutions related R&D in Finland and sales through different channels in over 60 countries. The company has an extensive portfolio of 55 international patents protecting the technology. In 2019, Optomed's revenue reached EUR 15 million and 2018 pro forma revenue amounted to EUR 14.5 million. At the end of 2019, Optomed employed 108 professionals.